



眾利股票精選

本专栏在本月2日推介祖龙娱乐(09990.HK)今天上市,现暂报\$18.48.较招股价\$11.68高出6.82,一手净赚\$6820。投资者可先沽出止赚,等大盘轻度回调后再次买入持有。中国手游板块在6月持续录得资金净流入,投资者如看好该板块可买入持有作中线投资。

今期推介的股票为中国生物制药(01177.HK)。集团覆盖医药研发、生产和销售全产业链,其产品包括多种生物药、化学药及中药现代化制剂。其全年业绩较去年增长约16.0%,约人民币24,234,030,000元。值得注意的是该集团在本年7月13日公布,集团开发的X射线造影剂「碘帕醇注射液」(商品名称:晴立达)已获得国家药监局颁发药品注册批件,通过仿制药质量和疗效一致性评价。该产品获批上市,将与集团现有的碘克沙醇注射液(商品名称:晴立明)形成差异化产品组合,加强集团在造影剂领域的实力。再加上6月10日特别报告提出2送1红股,(除净日本月20日),建议投资者可在\$15附近买入做中长线持有,止损价格为\$13。

中國生物製藥 (01177.HK) 現價 15.200 升跌 +0.180 (1.198%)

最後更新: 2020-07-15 11:17



<http://www.aastocks.com/tc/stocks/quote/detailchart.aspx?symbol=01177>

风险披露声明

有关资料乃根据或源自众利相信为可靠的数据源,惟对该些数据的准确性或可靠性众利不作任何陈述或保证(明示或暗示)。而所提供的资料或有关人士发表的意见并不构成及不应被视为买卖任何证券或投资的要约或该要约的招徕或恳求。众利及其高级人员、雇员、代理人及附属公司可能于电邮中提及的证券或投资拥有利益,但对于客户因使用或依赖此电邮所提供的数据而(直接或间接)遭受的损失或后果概不负责。

Risk Disclosure Statement

The materials contained herein are provided by Chung Lee Securities Company Limited ("Chung Lee") for information only. While such materials are based on or derived from sources believed to be reliable, Chung Lee makes no representation or warranty (express or implied) as to their accuracy or reliability. Neither the information nor the opinions expressed herein constitute, or are to be construed as, an offer or invitation or solicitation of an offer to buy or sell any securities or investments. Chung Lee and its officers, employees, agents and affiliates may have interests in the securities or investments covered herein and accept no liability whatsoever for any loss or consequence whatsoever (whether direct or indirect) resulting from any use of or reliance by you on such materials.
